骨肉瘤化学治疗的研究进展

Research progress of chemotherapy for osteosarcoma

骨肉瘤(osteosarcoma,OS)是临床骨科肿瘤中发病率最高的原发于骨组织恶性骨肿瘤,主要好发于儿童。骨肉瘤治疗总体难度较大,随着新辅助化疗和术后辅助化疗的出现,患者无病生存率和预后较前获得了较大的改善。然而骨肉瘤化疗的毒副作用,包括骨髓抑制反应、恶心、呕吐、脱发,黏膜炎症、生育能力的丧失及偶发过敏反应给患者带来一定的生理和心理上的伤害。同时骨肉瘤对化学药物的抵抗及耐药骨肉瘤细胞的出现,使得骨肉瘤的对当前化疗方案效果不太理想。该文对骨肉瘤化学治疗的研究进展作一综述。

Osteosarcoma is the most common malignant bone tumor of clinical orthopedic tumors.It is derived from mesenchymal tissue and mainly consists of spindle fibroblasts and osteoblasts,and predominates in children.The overall treatment of osteosarcoma is difficult.With the advent of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy,disease-free survival rate and prognosis have been greatly improved.However,the toxic and side effects of osteosarcoma chemotherapy,including myelosuppression,nausea,vomiting,hair loss,mucosal inflammation,loss of fertility and incidental allergic reactions,have caused physical and psychological damage to the patients.Simultaneously,Osteosarcoma resistance to chemical drugs and the emergence of resistant osteosarcoma cells make the treatment of osteosarcoma less effective than current chemotherapy regimens.In this paper,we review the chemotherapy of osteosarcoma to further illustrate the status and research progress of osteosarcoma chemotherapy